Peter van Wel leaves company after serving under temporary contract as member of executive board responsible for U.S. operations, Dutch firm announces Jan. 30. Personnel change is part of Royal Numico's effort to "redefine the responsibilities of the U.S. management team" following firm's announcement it will divest Rexall Sundown (1"The Tan Sheet" Nov. 11, 2002, p. 3). Numico is looking for a successor with retail experience to focus on GNC, which was put on "probation" and could face divestiture if its financial performance does not improve. Van Well's successor also will be charged with executing the divestments...

AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.

The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.